MSI-H
About
Biomarker Type: Microsatellite Stability
Present: True
Status: Microsatellite instability-high (MSI-H)
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | MSI-H | Any solid tumor | Pembrolizumab | FDA |
| Sensitivity (+) | MSI-H | Colorectal Adenocarcinoma | Pembrolizumab | FDA |
| Sensitivity (+) | MSI-H | Endometrial Carcinoma | Pembrolizumab | FDA |
| Sensitivity (+) | MSI-H | Endometrial Carcinoma | Dostarlimab | HC |
| Sensitivity (+) | MSI-H | Colorectal Adenocarcinoma | Pembrolizumab | HC |
| Sensitivity (+) | MSI-H | Any solid tumor | Pembrolizumab | HC |
| Sensitivity (+) | MSI-H | Colorectal Adenocarcinoma | Ipilimumab, Nivolumab | FDA |
| Sensitivity (+) | MSI-H | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | FDA |
| Sensitivity (+) | MSI-H | Colorectal Adenocarcinoma | Nivolumab | FDA |
| Sensitivity (+) | MSI-H | Colorectal Adenocarcinoma | Ipilimumab, Nivolumab | FDA |